Cargando…
Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161103/ https://www.ncbi.nlm.nih.gov/pubmed/35649593 http://dx.doi.org/10.1136/bmjopen-2022-062740 |
_version_ | 1784719415839817728 |
---|---|
author | Bénard, Angèle Chouinard, Sylvain Leavitt, Blair R Budd, Nathalie Wu, Jennifer W Schoffer, Kerrie |
author_facet | Bénard, Angèle Chouinard, Sylvain Leavitt, Blair R Budd, Nathalie Wu, Jennifer W Schoffer, Kerrie |
author_sort | Bénard, Angèle |
collection | PubMed |
description | OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) disease-modifying treatment (DMT). DESIGN, SETTING AND PARTICIPANTS: Using a case study, mixed methods framework, online surveys followed by semistructured interviews were conducted in late 2020 and early 2021. Neurologists from Canadian HD (n=16) and community (n=11) centres and social workers (n=16) were invited to complete online surveys assessing current HD management and potential capacity to support administration of an IT DMT. OUTCOME MEASURES: Survey responses, anticipated demand and assumed resource requirements were modelled to reveal capacity to treat (ie, % of eligible patients) by centre. Resource bottlenecks and incremental support required (full-time equivalent, FTE) were also determined. RESULTS: Neurologists from 15/16 HD centres and 5/11 community centres, plus 16/16 social workers participated. HD centres manage 94% of patients with HD currently seeking care in Canada, however, only 20% of IT DMT-eligible patients are currently seen by neurologists. One-third of centres have no access to nursing support. The average national incremental nursing, room, neurologist and social worker support required to provide IT DMT to all eligible patients is 0.73, 0.36, 0.30 and 0.21 FTE per HD centre, respectively. At peak demand, current capacity would support the treatment of 6% of IT DMT-eligible patients. If frequency of administration is halved, capacity for IT-DMT administration only increases to 11%. CONCLUSIONS: In Canada, there is little to no capacity to support the administration of an IT DMT for HD. Current inequitable and inadequate resourcing will require solutions that consider regional gaps and patient needs. |
format | Online Article Text |
id | pubmed-9161103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91611032022-06-16 Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs Bénard, Angèle Chouinard, Sylvain Leavitt, Blair R Budd, Nathalie Wu, Jennifer W Schoffer, Kerrie BMJ Open Neurology OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) disease-modifying treatment (DMT). DESIGN, SETTING AND PARTICIPANTS: Using a case study, mixed methods framework, online surveys followed by semistructured interviews were conducted in late 2020 and early 2021. Neurologists from Canadian HD (n=16) and community (n=11) centres and social workers (n=16) were invited to complete online surveys assessing current HD management and potential capacity to support administration of an IT DMT. OUTCOME MEASURES: Survey responses, anticipated demand and assumed resource requirements were modelled to reveal capacity to treat (ie, % of eligible patients) by centre. Resource bottlenecks and incremental support required (full-time equivalent, FTE) were also determined. RESULTS: Neurologists from 15/16 HD centres and 5/11 community centres, plus 16/16 social workers participated. HD centres manage 94% of patients with HD currently seeking care in Canada, however, only 20% of IT DMT-eligible patients are currently seen by neurologists. One-third of centres have no access to nursing support. The average national incremental nursing, room, neurologist and social worker support required to provide IT DMT to all eligible patients is 0.73, 0.36, 0.30 and 0.21 FTE per HD centre, respectively. At peak demand, current capacity would support the treatment of 6% of IT DMT-eligible patients. If frequency of administration is halved, capacity for IT-DMT administration only increases to 11%. CONCLUSIONS: In Canada, there is little to no capacity to support the administration of an IT DMT for HD. Current inequitable and inadequate resourcing will require solutions that consider regional gaps and patient needs. BMJ Publishing Group 2022-06-01 /pmc/articles/PMC9161103/ /pubmed/35649593 http://dx.doi.org/10.1136/bmjopen-2022-062740 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Neurology Bénard, Angèle Chouinard, Sylvain Leavitt, Blair R Budd, Nathalie Wu, Jennifer W Schoffer, Kerrie Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title | Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title_full | Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title_fullStr | Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title_full_unstemmed | Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title_short | Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs |
title_sort | canadian healthcare capacity gaps for disease-modifying treatment in huntington’s disease: a survey of current practice and modelling of future needs |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161103/ https://www.ncbi.nlm.nih.gov/pubmed/35649593 http://dx.doi.org/10.1136/bmjopen-2022-062740 |
work_keys_str_mv | AT benardangele canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds AT chouinardsylvain canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds AT leavittblairr canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds AT buddnathalie canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds AT wujenniferw canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds AT schofferkerrie canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds |